 |
1 Product |  |
0 Diseases | | 1 Product |
|
3 Trials |  |
352 News |  |
| «12345» |
- || INO-4800 / Inovio, The Wistar Institute
U owe #INO & it’s honorable & dedicated scientist an APOLOGY for slandering there reputation! Prove U have changed & write the truth about this Honorable company! @AOC @SenWarren @CDCDirector @DrWoodcockFDA @VP people r dying & #INO4800 is the answer! #Dr.Fauci knows the truth (Twitter) - Feb 2, 2021
- | INO-4800 / Inovio, The Wistar Institute
@InovioPharma INO 4800 a better solution. (Twitter) - Jan 31, 2021
- || INO-4800 / Inovio, The Wistar Institute
Trial completion date, Trial primary completion date: Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers (clinicaltrials.gov) - Jan 22, 2021
P1, N=120, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Jul 2021 --> Jan 2022 | Trial primary completion date: Jul 2021 --> Jan 2022
- ||| INO-4800 / Inovio, The Wistar Institute
Please see what you can do to help expedite Inovio Pharmaceuticals CoVid vaccine INO-4800. It's ultra safe, highly effective, can be boosted and requires no cold chain. (Twitter) - Jan 21, 2021
- ||| INO-4800 / Inovio, The Wistar Institute
Clinical, P1 data: It’s so disappointing. With Hilda I asked if she promised to provide commentary on phase 1 prior to it being released. Then I was blocked for asking questions about safety of vaccines. Her only tweet about ino-4800 ph1 may as well have been a nothing burger. (Twitter) - Jan 20, 2021
- || INO-4800 / Inovio, The Wistar Institute
I’ve been blocked now by @EricTopol @hildabast about commenting on ino-4800 next is @PeterHotez and @DrEricDing I guess. Although I do like their commentary. (Twitter) - Jan 20, 2021
- ||| INO-4800 / Inovio, The Wistar Institute
This vaccine has CD8+ data included -- are you saying this might suggest ADE? it's INO-4800 fro, INOVIO btw (Twitter) - Jan 19, 2021
- ||||| INO-4800 / Inovio, The Wistar Institute
Clinical, Review: A follow up of INO-4800 AE profile from Peer Review. It also elicited 100% immune response with respectable NAB and T-cells. absolutely no comparison between mRNA and dna plasmid with cellectra with regards to tolerability and safety.. none #covid19 #vaccine $ino (Twitter) - Jan 15, 2021
- || INO-4800 / Inovio, The Wistar Institute
Repeat after me 3 times Inovio - INO-4800 (Twitter) - Jan 9, 2021
- ||| INO-4800 / Inovio, The Wistar Institute
🧬Did you here about the 3rd one being held back. It’s not a secret. INO-4800. Learn more @INOVIO.com🧬 (Twitter) - Jan 8, 2021
- || INO-4800 / Inovio, The Wistar Institute
Clinical, P1 data, Journal: Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. (Pubmed Central) - Jan 5, 2021
P1
INO-4800 demonstrated excellent safety and tolerability and was immunogenic in 100% (38/38) of the vaccinated subjects by eliciting either or both humoral or cellular immune responses. Coalition for Epidemic Preparedness Innovations (CEPI).
- || INO-4800 / Inovio, The Wistar Institute
#INO4800 P2 is alrdy underway in China based on promising data from US & Chinese P1 trials. The latter started in Aug. while the US P1 started in April & completed in June. Why @InovioPharma's P2 has been held back for so long? @US_FDA favoring BPs? @EricTopol @DrEricDing (Twitter) - Jan 4, 2021
- [VIRTUAL] Molecular insight of SARS-CoV-2: viral structure, infection mechanism, antiviral agents, and vaccine development () - Dec 26, 2020 - Abstract #ASHP2020ASHP_2846;
Currently, companies in late-phase trials such as Moderna, Pfizer, AstraZeneca, Inovio, Johnson and Johnson, and Novavax are on their way to developing a successful vaccine. As for an antiviral drug, Remdesivir is available through the FDA Emergency Use Authorization that has shown to benefit hospitalized individuals with severe SARS-CoV-2 for a 5- or 10-day therapy regimen.
- ||||| INO-4800 / Inovio, The Wistar Institute
P1 data, Review: The potential for high rate of Adverse reactions has always been a known based on phase 1 data from all the vaccine candidates. So far moderna and Pfizer have rung true. Especially the second dose. We are waiting for peer review data of ino-4800 to be published (Twitter) - Dec 22, 2020
- ||| INO-4800 / Inovio, The Wistar Institute
Would be nice if @SteveFDA & @CDCDirector can be trusted but so far, they have NOT been transparent with the American public! Operation “Select Speed” has held @InovioPharma #INO4800 back when they are the most transparent & safest #Covid_19 data to date! The truth will come out! (Twitter) - Dec 20, 2020
- ||| INO-4800 / Inovio, The Wistar Institute
Clinical: I really don’t think a pragmatic epidemiologist is going to prefer one over the other given the severity of the situation. That’s not take away from INO-4800 as we will need a half dozen or more vaccines. (Twitter) - Dec 13, 2020
- || INO-4800 / Inovio, The Wistar Institute
ارتفاع $INO بعد اعلان شراكه جديدة مع شركة Kaneka Eurogentec S.A! لتصنيع لقاح INO-4800 المخصص لمعالجة فيروس كرورنا ! هذه تعتبر الشراكة الثانية بعد Thermo Fisher قبل شهرين تقريباً! @thermofisher @InovioPharma (Twitter) - Dec 3, 2020
- || INO-4800 / Inovio, The Wistar Institute
Adverse events: @InovioPharma #DNAMedicine #DNAVaccine @ThermoFisherPR @JoeBiden @DrBiden #INO4800 No call chain problems, no side effects. @OlogyBio (Twitter) - Dec 3, 2020
- | INO-4800 / Inovio, The Wistar Institute
.. @thermofisher plans 100 million doses of #INO4800 annually. (Twitter) - Dec 3, 2020
- |||||| INO-4800 / Inovio, The Wistar Institute
Enrollment open: INNOVATE: Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure (clinicaltrials.gov) - Dec 3, 2020
P2/3, N=6578, Recruiting, Sponsor: Inovio Pharmaceuticals
As for an antiviral drug, Remdesivir is available through the FDA Emergency Use Authorization that has shown to benefit hospitalized individuals with severe SARS-CoV-2 for a 5- or 10-day therapy regimen. Not yet recruiting --> Recruiting
- |||| INO-4800 / Inovio, The Wistar Institute
Adverse events: @PeterHotez INO4800 is the ONLY vaccine with no deep freezing needed, 1 yr room temperature durability and no adverse side effects ONLY redness on injection site. Please help Inovio save lives (Twitter) - Nov 24, 2020
- |||||||||| INO-4800 / Inovio, The Wistar Institute
New P2/3 trial: INNOVATE: Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure (clinicaltrials.gov) - Nov 23, 2020
P2/3, N=6578, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- |||| INO-4800 / Inovio, The Wistar Institute
Adverse events: @CDCDirector How can operation warp speed give a major bump for Moderna and NOVAVAX that need refrigeration and deep freezing whereas INO4800 from Inovio HAS 1 year lasting in room temperature with no adverse side effects. A shame! #actnow #savelives (Twitter) - Nov 18, 2020
- | INO-4800 / Inovio, The Wistar Institute
$INO INO-4800 a top-10 vaccine candidate - Benchmark. Maintains Buy, PT $25 (Twitter) - Nov 17, 2020
- |||| INO-4800 / Inovio, The Wistar Institute
Clinical: That's not enough! Need vaccine w/ near 100% & lasting efficacy! #INO-4800 #Inovio @drsanjaygupta @US_FDA @CDCDirector @CDCgov BioNTech scientist: Vaccine could halve virus transmission https://t.co/va68ptU4oe (Twitter) - Nov 15, 2020
- |||| #Inovio $INO #INO4800 #INO5401 #GBM data on the 19th #VIN #AIN data #ZIKA data #SNO2020 #VGX3100 (Twitter) - Nov 4, 2020
- ||| #Inovio $INO #INO4800 #INO5401 #GBM data on the 19th #VIN #AIN data #ZIKA data #SNO2020 #VGX3100 $REGN (Twitter) - Nov 2, 2020
- |||| INO-4800 / Inovio, The Wistar Institute
Clinical: INO 4800 is the way to go!!!!!!! Yrs of vaccine data on safety and efficacy related to coronavirus (MERS/Covid) (Twitter) - Oct 31, 2020
- | INO-4800 / Inovio, The Wistar Institute
Journal: Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein. (Pubmed Central) - Oct 23, 2020
Through this approach, supported by biomolecular modelling of this mutation and the commonly-associated P314L mutation in the RNA-dependent RNA polymerase, we have shown that there is no experimental evidence to support this speculation. We additionally demonstrate that the putative elastase cleavage site introduced by the D614G mutation is unlikely to be accessible to proteases.
- || INO-4800 / Inovio, The Wistar Institute
Sir @InovioPharma #INO4800 (Twitter) - Oct 22, 2020
- | VK-2019 / The Wistar Institute, Stanford University
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Oct 19, 2020
P1/2, N=14, Terminated, Sponsor: Cullinan Oncology, LLC
We additionally demonstrate that the putative elastase cleavage site introduced by the D614G mutation is unlikely to be accessible to proteases. N=60 --> 14 | Trial completion date: Jun 2023 --> Aug 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2021 --> Jun 2020; Lack of efficacy
- || INO-4800 / Inovio, The Wistar Institute
Ffs! @InovioPharma hasn’t published data to allow anyone to claim they generate any sort of immune response to INO-4800 never mind a ‘balanced’ one. Please get off the pony and start lobbying them to pull their finger out rather than slating others (Twitter) - Oct 14, 2020
- ||| INO-4800 / Inovio, The Wistar Institute
Clinical: Your least favorite #Inovio has the answer. #DNAMedicine #INO4800 A partial clinical hold due to the device sure beats $JNJ ‘s, Unexplained illness hold. $INO #BecauseTheWorldCantWait. (Twitter) - Oct 12, 2020
- ||| INO-4800 / Inovio, The Wistar Institute
#INO4800 found equally effective against COVID-19 D & G strains by Australian researchers! @CEPIvaccines @gatesfoundation @US_FDA @SteveFDA @CDCgov @CDCDirector @InovioPharma @WHO @inoviolt (Twitter) - Oct 8, 2020
- ||| INO-4800 / Inovio, The Wistar Institute
Inovio INO-4800 (Twitter) - Sep 20, 2020
- || INO-4800 / Inovio, The Wistar Institute
Do you have #DNA INO-4800 in your Covid19 collection? (Twitter) - Sep 14, 2020
- ||| INO-4800 / Inovio, The Wistar Institute
Is @InovioPharma claims of their covid vaccine is true. Can any of you please share your thoughts on another nucleic acid-based #COVID19 vaccine candidate INO-4800. @elliott_blkwd (Twitter) - Sep 12, 2020
- || INO-4800 / Inovio, The Wistar Institute
DNA platform #ino4800 may hold the answer. (Twitter) - Sep 12, 2020
- | INO-4800 / Inovio, The Wistar Institute
🧬INO-4800.only safe vaccine🧬 I-N-O-V-I-O🧬 (Twitter) - Sep 8, 2020
- || INO-4800 / Inovio, The Wistar Institute
And yes, Samsung too. We see INO-4800 can open a lot of doors for Inovio. (Twitter) - Sep 8, 2020
- | INO-4800 / Inovio, The Wistar Institute
Approve Leronimab and INO-4800 (Twitter) - Sep 1, 2020
- ||| INO-4800 / Inovio, The Wistar Institute
Enrollment open: Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19 (clinicaltrials.gov) - Aug 19, 2020
P1/2, N=160, Recruiting, Sponsor: International Vaccine Institute
N=60 --> 14 | Trial completion date: Jun 2023 --> Aug 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2021 --> Jun 2020; Lack of efficacy Not yet recruiting --> Recruiting
- |||| INO-4800 / Inovio, The Wistar Institute
Clinical, Adverse events: Dr. Fauci, Inovio's INO-4800 shows 94% or higher effectiveness w/o any serious side effect in a Phase 1 clinical trial on humans! Yet little coverage of this in media! @realDonaldTrump @CEPIvaccines @CDCDirector @BillGates @TIME @InovioPharma @inoviolt https://t.co/bhFsves3xm (Twitter) - Aug 12, 2020
- || INO-4800 / Inovio, The Wistar Institute
Enrollment closed: Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers (clinicaltrials.gov) - Aug 11, 2020
P1, N=120, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| INO-4800 / Inovio, The Wistar Institute
New P1/2 trial: Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19 (clinicaltrials.gov) - Jun 25, 2020
P1/2, N=160, Not yet recruiting, Sponsor: International Vaccine Institute
- || VK-2019 / The Wistar Institute, Stanford University
Enrollment closed: Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Jun 17, 2020
P1/2, N=60, Active, not recruiting, Sponsor: Cullinan Apollo Corporation
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | INO-4800 / Inovio, The Wistar Institute
It easy, use @InovioPharma INO-4800. (Twitter) - Jun 9, 2020
- || INO-4800 / Inovio, The Wistar Institute
Enrollment change, Trial completion date, Trial primary completion date: Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers (clinicaltrials.gov) - Jun 4, 2020
P1, N=120, Recruiting, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting N=40 --> 120 | Trial completion date: Apr 2021 --> Jul 2021 | Trial primary completion date: Apr 2021 --> Jul 2021
- | INO-4800 / Inovio, The Wistar Institute
Journal: Immunogenicity of a DNA vaccine candidate for COVID-19. (Pubmed Central) - May 27, 2020
Following immunization of mice and guinea pigs with INO-4800 we measure antigen-specific T cell responses, functional antibodies which neutralize the SARS-CoV-2 infection and block Spike protein binding to the ACE2 receptor, and biodistribution of SARS-CoV-2 targeting antibodies to the lungs. This preliminary dataset identifies INO-4800 as a potential COVID-19 vaccine candidate, supporting further translational study.
- ||| INO-4800 / Inovio, The Wistar Institute
Preclinical: $INO #COVID19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models (Twitter) - May 20, 2020